About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
FATE - Fate Therapeutics| Previous Close | $81.42 | Open | |
| Volume | Market Cap | 7.702B | |
| Yield | Last Dividend |
| Fate Therapeutics Appoints Mark Plavsic,... | 06/15/21 |
| SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the devel... | |
| Fate Therapeutics: Strong Early Stage Da... | 06/13/21 |
| No summary available. | |
| Heres Why FATEs Stock Priced Popped | 06/08/21 |
| Investors Alley Heres Why FATEs Stock Priced Popped FATEs stock price was higher on Friday because Fate Therapeutics (FATE) highlighted positive inter... | |
| BMO Capital Stick to Their Hold Rating f... | 06/07/21 |
| BMO Capital Stick to Their Hold Rating for Fate Therapeutics | |
| Oppenheimer Stick to Their Buy Rating fo... | 06/06/21 |
| Oppenheimer Stick to Their Buy Rating for Fate Therapeutics | |
| STAT+: Fate Therapeutics natural killer ... | 06/04/21 |
| Fate Therapeutics said an experimental, off-the-shelf immunotherapy made from natural killer cells helped shrink tumors for some blood cancer patients... | |
| Fate Therapeutics (FATE) falls 3.47% for... | 05/19/21 |
| Fate Therapeutics (NASDAQ: FATE) shares fell -3.47% to end trading Wednesday at $75.32 per share - a net change of $-2.71. Shares traded between $78.7... | |
| Leerink Partners Keeps a Buy Rating on F... | 05/18/21 |
| In a report issued on May 14, Daina Graybosch from Leerink Partners maintained a Buy rating on Fate Therapeutics (FATE). The companys shares The post... | |
| Analysts Offer Insights on Healthcare Co... | 05/14/21 |
| Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE), Flexion Therapeutics (FLXN)... | |
| Fate Therapeutics'' iPSC-Derived Cell Th... | 05/14/21 |
| Fate Therapeutics Inc (NASDAQ: FATE ) has announced interim data from Phase 1 data from the Company''s off-the-shelf, iPSC-derived natural killer (NK)... | |
| Analysts Are Bullish on Top Healthcare S... | 05/13/21 |
| Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Templates (MTEM), Fate Therapeutics The post ... | |
| Fate Therapeutics posts interim results ... | 05/13/21 |
| No summary available. | |
| Fate Therapeutics Announces Encouraging ... | 05/13/21 |
| 4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow | |
| Mizuho Securities Reaffirms Their Buy Ra... | 05/11/21 |
| Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Fate Therapeutics (FATE) today and set a price target of $109.00. The post Mizuho ... | |
| Fate Therapeutics, Inc. (NASDAQ:FATE) Fo... | 05/11/21 |
| Fate Therapeutics, Inc. (NASDAQ:FATE) Investment analysts at Wedbush issued their FY2025 earnings per share (EPS) estimates for Fate Therapeutics in ... | |
| Piper Sandler Weighs in on Fate Therapeu... | 05/11/21 |
| Fate Therapeutics, Inc. (NASDAQ:FATE) Equities researchers at Piper Sandler reduced their Q2 2021 earnings per share estimates for Fate Therapeutics ... | |
| Fate Therapeutics Inc. Shares Close the ... | 03/31/21 |
| Fate Therapeutics Inc. shares closed today 11.3% higher than it did at the end of yesterday. The stock is currently down 18.5% year-to-date, up 219.9... | |
| Fate Therapeutics Inc. Shares Close the ... | 03/09/21 |
| Fate Therapeutics Inc. shares closed today 11.8% higher than it did at the end of yesterday. The stock is currently down 2.7% year-to-date, up 256.4%... | |
| Fate Therapeutics Inc. Shares Climb 0.2%... | 01/14/21 |
| Fate Therapeutics Inc. shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $9B. The stock is currently up 24... | |
| Fate Therapeutics Inc. Shares Close the ... | 01/07/21 |
| Fate Therapeutics Inc. shares closed today 17.5% higher than it did at the end of yesterday. The stock is currently up 9.7% year-to-date, up 403.7% o... | |
| Fate Therapeutics Inc. Shares Climb 16.1... | 01/07/21 |
| Fate Therapeutics Inc. shares closed 16.1% higher than its previous 52 week high, giving the company a market cap of $8B. The stock is currently up 9... | |
| Fate Therapeutics Inc. Shares Near 52-We... | 01/06/21 |
| Fate Therapeutics Inc. shares closed today at 1.2% below its 52 week high of $100.95, giving the company a market cap of $7B. The stock is currently ... | |
| Fate Therapeutics Inc. Shares Close the ... | 01/06/21 |
| Fate Therapeutics Inc. shares closed today 15.1% higher than it did at the end of yesterday. The stock is currently down 4.6% year-to-date, up 354.0%... | |
| Fate Therapeutics Inc. Shares Close the ... | 12/11/20 |
| Fate Therapeutics Inc. shares closed the week 60.3% higher than it did at the end of last week. The stock is currently up 394.9% year-to-date, up 412... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
